To exploit this vulnerability, sigvotatug vedotin (SV), formerly known as SGN-B6A, has been developed as an ITGB6-directed ADC, representing a novel approach to targeted therapy in HNSCC and other ITGB6-driven malignancies [143]. The gene discussed is ITGB6; the disease is head and neck squamous cell carcinoma.